Replacement of GC Mass Spectrometer

描述（由申请人提供）：我们正在申请资金，以更换1999年安装的用于定量小挥发性脂质的ThermoFisher单四极杆Trace MS GC质谱仪。去年，大约47%的分析是在Trace MS上进行的。电子、计算机和软件的改进使该仪器的功能落后了几代人，我们有一些用户需要新的串联MS/MS仪器的灵敏度和功能。我们选择用ThermoFisher公司的TSQ量子GC三重四极串联质谱仪取代痕量质谱仪。检测灵敏度和可靠性是我们评价的主要因素。与痕量GC接口的TSQ量子GC将安装在位于维克森林大学医学院（WFUSM）的质谱仪设施中。三个质谱仪，专门从事不同类型的分析位于质谱仪设施。肽测序使用Waters Q-TOF API US串联质谱仪连接Waters CapLC。常规磷脂分析在TSQ Discovery Max三重四极杆质谱仪上进行，该质谱仪与更新的Agilent 1100 HPLC接口。TSQ Quantum GC MS/MS将取代用于分析小挥发性脂质的Trace MS。该基金的网页是http://www1.wfubmc.edu/mass_spec/。有三个人与基地有关。设施主任迈克尔·托马斯博士帮助用户设计和实施实验，然后帮助他们解释结果。有两名技术人员可以进行样品分析。其中一名技术人员约翰·欧文博士精通样品制备，他将为调查人员制作样品或帮助他们设计样品制作方案。鼓励学生和博士后在经过适当的培训后使用设备。自1981年以来，质谱仪设施为WFUSM的研究人员提供了质谱资源。在过去的25年里，该设施的年使用量一直在增加。在过去的三年中，该设施为来自11个部门的36名WFUSM研究者及其合作者和6名与WFUSM无关的学术研究者提供服务。维克森林大学综合癌症中心（CCCWFU）、收费服务和该机构致力于支持该设施。在2008财政年度，该设施的成本为166,816美元，其中57%由按服务收费支付，43%由CCCWFU支付。该机构没有自付费用。该基金支持的赠款总价值超过1300万美元。由于WFUSM教师和学生大量使用痕量质谱仪，因此必须维护一台具有最佳灵敏度和分辨率的质谱仪，这是商业上可用的。

DESCRIPTION (provided by applicant): We are applying for funds to replace the ThermoFisher single quadrupole Trace MS GC mass spectrometer that was installed in 1999 and that is used to quantify small volatile lipids. In the last year about 47% of all analyses were performed on the Trace MS. Improvements in electronics, computers, and software have put the capabilities of this instrument several generations behind and we have several users that need the sensitivity and capabilities routinely available on newer tandem MS/MS instruments. We have chosen to replace the Trace MS with a triple quadrupole tandem mass spectrometer, the TSQ Quantum GC from ThermoFisher Corporation. Detection sensitivity and reliability were the principal factors in our evaluation. The TSQ Quantum GC interfaced to a Trace GC will be installed in the Mass Spectrometer Facility located at Wake Forest University School of Medicine (WFUSM). Three mass spectrometers that specialize in different types of analyses are located in the Mass Spectrometer Facility. Peptide sequencing is performed using a Waters Q-TOF API US tandem mass spectrometer interfaced to a Waters CapLC. Routine phospholipid analysis is performed on the TSQ Discovery Max triple quadrupole mass spectrometer interfaced with an updated Agilent 1100 HPLC. The TSQ Quantum GC MS/MS will replace the Trace MS that is used for the analysis of small, volatile lipids. The Facility webpage is at http://www1.wfubmc.edu/mass_spec/. There are three individuals associated with the Facility. The Facility Director, Dr. Michael Thomas, helps users design and implement experiments and then helps them interpret the results. Two technicians are available to run sample analyses. One of the technicians, Dr. John Owen, is well versed in sample preparation and will work up samples for investigators or help them design sample work up protocols. Students and postdoctoral fellows are encouraged to use the equipment after appropriate training. The Mass Spectrometer Facility has offered mass spectrometric resources to WFUSM investigators since 1981. Yearly use of the facility has consistently increased over the past 25 years. During the past three years the facility served 36 WFUSM investigators and their collaborators from 11 departments and 6 academic investigators not associated with WFUSM. The Comprehensive Cancer Center of Wake Forest University (CCCWFU), fee-for-service and the Institution are committed to support the facility. In Fiscal 2008 the cost of the facility was $166,816 with 57% covered by fee-for-service and 43% covered by CCCWFU. There was no out-of-pocket cost to the Institution. This Facility supports grants with a combined value of more than $13M. Because of the heavy usage of the Trace MS by WFUSM faculty and students it is essential to maintain a mass spectrometer that operates with the best sensitivity and resolution that is commercially available. PUBLIC HEALTH RELEVANCE: The Mass Spectrometer Facility supports NIH-funded research at Wake Forest University and GC/MS capability is an essential part of that support. Replacing our GC/MS with a new instrument having added capabilities will enhance the timely completion of NIH-funded research.